Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

4912 - A phase Ib/II study of AK104, a PD-1/CTLA-4 Bispecific Antibody, Combined With mXELOX as First-line Therapy for Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Date

29 Sep 2019

Session

Poster Display session 2

Presenters

Jiafu Ji

Citation

Annals of Oncology (2019) 30 (suppl_5): v253-v324. 10.1093/annonc/mdz247

Authors

J. Ji1, L. Shen2, Z. Li1, X. Gao1, J. Gong2, D. Liu2, X. Wu1, S. Xu3, X. Jin3, B. Li3, M. Wang3, Y. Xia3

Author affiliations

  • 1 Key Laboratory Of Carcinogenesis And Translational Research (ministry Of Education/beijing), Gastrointestinal Tumor Center, Peking University Cancer Hospital & Institute, 100142 - Beijing/CN
  • 2 Department Of Gastrointestinal Oncology, Key Laboratory Of Carcinogenesis And Translational Research (ministry Of Education), Peking University Cancer Hospital & Institute, 100142 - Beijing/CN
  • 3 Clinical Research, Akeso Biopharma, Inc., 528400 - Zhongshan/CN
More

Resources

Abstract 4912

Background

AK104 is a tetravalent bispecific human IgG1 antibody, targeting two clinically validated receptors, PD-1 and CTLA-4. This bispecific antibody is designed based on Akeso Tetrabody platform (AACR, 2018). AK104 introduces novel T cell targeting MOAs that may provide an improved therapeutic index and a favorable toxicity profile when compared to the PD-1 and CTLA-4 combinations. In addition, we have shown increased avidity of AK104 binding to PD-1 and CTLA-4 compared to the combinations. The combination therapy with anti-PD-1 and anti-CTLA-4 agents is approved by FDA for metastatic melanoma, renal cell carcinoma and MSI-H/dMMR colorectal cancer. The efficacy of these drug combinations is dose dependent, and the toxicity associated with anti-CTLA-4 agents in particular is dose limiting, thereby potentially limiting full potential for combination therapy. Despite recent advances, the prognosis of patients with advanced gastric cancer remains poor. AK104 may show improved efficacy and safety in comparison to the combination of conventional anti-PD-1/L1 and anti-CTLA-4 antibodies.

Trial design

This multicenter, open-label, phase Ib/II study will evaluate the safety and efficacy of AK104 in combination with oxaliplatin and capecitabine (mXELOX) as first-line therapy in patients with advanced gastric or GEJ adenocarcinoma. The dose-escalation phase will evaluate three dose levels (4mg/kg, 6mg/kg, and 10mg/kg Q2W) to identify a maximum tolerated dose (MTD). Selected cohorts will be expanded up to a total of 18 patients per cohort to further establish the recommended Phase 2 dose (RP2D). Dose escalation and expansion phase will be followed by dose confirmation phase (Phase II) which will further characterize the treatment of AK104 in combination at RP2D. The primary endpoints are safety and efficacy (ORR in Phase II). Secondary endpoints include additional efficacy (PFS, DoR), pharmacokinetics, PD and immunogenicity. Exploratory endpoints include efficacy according to immune-related RECIST and correlations between potential biomarkers (PD-L1 expression, TMB) and clinical activity.

Clinical trial identification

NCT03852251.

Editorial acknowledgement

Legal entity responsible for the study

Peking University Cancer Hospital & Institute, Beijing, China.

Funding

Akeso Biopharma, Inc., Zhongshan, China.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings